Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00590239 · ClinicalTrials.gov registry record
Barrett's Esophagus Related Neoplasia (BERN) Project
A clinical trial of Neoplasms and Gastroesophageal Reflux, sponsored by Midwest Biomedical Research Foundation.
- Recruiting
- Registry status
- 150
- Enrollment target
- 1
- Study location
NCT00590239 is a study of Neoplasms and Gastroesophageal Reflux that is actively recruiting participants, run by Midwest Biomedical Research Foundation. The registered enrollment target is 150 participants, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00590239, a study of Neoplasms and Gastroesophageal Reflux, is actively recruiting participants, sponsored by Midwest Biomedical Research Foundation.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
* The use of high resolution endoscopy (HRE), narrow band imaging (NBI) and chromoendoscopy increases the detection rates of Barrett's esophagus (BE) and early neoplasia. * Endoscopic mucosal resection (EMR) will improve the accuracy for detection of dysplasia/early neoplasia. Specific Aim 1 - To create a video-atlas of non-dysplastic and dysplastic/early neoplastic lesions in patients with BE. This will be used for training purposes and to assess learning curve associated with these new technologies. Specific Aim 2 - To create a standardized classification system for the mucosal and vascular patterns observed in patients with BE. Specific Aim 3 - To determine the interobserver agreement using the video-atlas for the mucosal and vascular patterns classification agreed upon. Specific Aim 4 - To determine the endoscopic detection rate of esophageal cancer or precancerous lesions removed during endoscopy. Specific Aim 5 - To determine the pathologic and clinical outcomes of patients undergoing EMR/ablation; including morbidity, mortality and complications of the procedure. Results to date (June 2008) : this study is active and open to enrollment. Currently 26 patients have enrolled in this study at the Kansas City VA medical center. In order to participate, patients must be eligible for care at the KCVA hospital.
Conditions Studied
Study Locations (1)
Missouri
- Kansas city VA Medical center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2007-05-15 |
| Est. Completion | 2026-12-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00590239
The ClinicalTrials.gov registry entry for NCT00590239 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,620-participant average among 158 other Neoplasms trials with a reported enrollment target (91% lower). The listed sponsor is Midwest Biomedical Research Foundation, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Neoplasms appearing as the primary indexed condition, and to 0 interventions.
NCT00590239 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT00590239 about?
NCT00590239 is a clinical study titled "Barrett's Esophagus Related Neoplasia (BERN) Project". * The use of high resolution endoscopy (HRE), narrow band imaging (NBI) and chromoendoscopy increases the detection rates of Barrett's esophagus (BE) and early neoplasia. * Endoscopic mucosal resection (EMR) will improve the accuracy for detection of dysplasia/early neoplasia. Specific Aim 1 - To c...
What is the current status of trial NCT00590239?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2007-05-15. Estimated completion is 2026-12-30.
What conditions does trial NCT00590239 study?
This clinical trial studies the following conditions: Neoplasms, Gastroesophageal Reflux, Barrett's Esophagus.
Who is sponsoring clinical trial NCT00590239?
This trial is sponsored by Midwest Biomedical Research Foundation, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00590239 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
Real World Registry for Use of the Ion Endoluminal System
RECRUITING
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Endometrial Cell Collection With the PadKit
RECRUITING · NA
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Resilience in East Asian Immigrants for Advance Care Planning Discussions
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.